Bromodomain and extra-terminal motif (BET) · PROTEIN FAMILY · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Bromodomain and extra-terminal motif (BET) shows late clinical disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 4 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P25440. Start with neoplasm, then reuse UniProt P25440 as the stable protein anchor across project notes and exports.
Start with neoplasm, then reuse UniProt P25440 as the stable protein anchor across project notes and exports.
Bromodomain and extra-terminal motif (BET) shows late clinical disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 4 linked drugs remain visible in the same block.
Start review with neoplasm because it currently carries late clinical support. Linked drugs include EZOBRESIB, MOLIBRESIB, PELABRESIB, RO-6870810. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyBromodomain-containing protein 2
Review this target as Bromodomain and extra-terminal motif (BET), mapped to UniProt P25440. ChEMBL maps the protein component as Bromodomain-containing protein 2. Sequence length is 801 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Bromodomain and extra-terminal motif (BET) as ChEMBL target CHEMBL4296614, mapped to UniProt P25440. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Bromodomain and extra-terminal motif (BET) is the right protein anchor across sources, using UniProt P25440 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why neoplasm is currently framed as late clinical support. It currently carries 4 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Bromodomain and extra-terminal motif (BET) |
| Target Type | PROTEIN FAMILY |
| Organism | Homo sapiens |
| UniProt | P25440 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Bromodomain-containing protein 2 |
| UniProt Accession | P25440 |
| Component Type | Protein |
| Sequence Length | 801 aa |
Bromodomain-containing protein 2
Review this target as Bromodomain and extra-terminal motif (BET), mapped to UniProt P25440. ChEMBL maps the protein component as Bromodomain-containing protein 2. Sequence length is 801 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Bromodomain and extra-terminal motif (BET) shows late clinical disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block.
Start review with neoplasm because it currently carries late clinical support. Linked drugs include EZOBRESIB, MOLIBRESIB, PELABRESIB, RO-6870810. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 26 | 0 | — |